News

Pharmaceutical company AgeneBio recently announced the publication of results of a Phase 2 clinical trial based on the company’s therapeutic product AGB101 for the pre-dementia stage of Alzheimer’s disease in the journal NeuroImage: Clinical. The study entitled “Response of the medial temporal lobe network in…

A recently published study conducted by a team of researchers from Harvard Medical School, Boston, suggests that the currently held assumptions about the pathogenic mutation process associated with the onset of inherited or familial Alzheimer’s disease (FAD) may be inaccurate. The study entitled “Presenilin-1 Knock-in Mice Reveal…

Scientists at Australia’s University of Queensland have found that non-invasive ultrasound technology can be used to break up neurotoxic amyloid plaques that cause memory loss and cognitive decline in persons afflicted with Alzheimer’s Disease (AD), which affects more than two-thirds of dementia patients. The discovery is elucidated in a paper…

A recent study revealed that heart function is an important risk factor in the development of dementia and Alzheimer’s disease. The study entitled “Low Cardiac Index is Associated with Incident Dementia and Alzheimer’s Disease: The Framingham Heart Study” was published in Circulation by…

According to a recent study conducted by a researcher from the University of Eastern Finland, the cognitive functioning of patients with Alzheimer’s disease and their behavioral and psychological difficulties are associated with their daily living activities. However, the researchers found that deficits in cognitive performance were not associated…

According to a recent study from researchers at the Keck School of Medicine of the University of Southern California, reduced expression of a protein called GLUT1, responsible for moving glucose in the brain-blood barrier (BBB) worsens Alzheimer’s disease cerebrovascular degeneration, neuropathology and cognitive function, suggesting that GLUT1 may represent…

The Alzheimer’s Drug Discovery Foundation (ADDF) is proud to announce that it is the Official Charity Partner of the 2015 TCS New York City Marathon. The Foundation is inviting runners that were not able to secure individual spots in the 2015 TCS New York City Marathon to be part of the Runners for Alzheimer’s…

The documentary “Looks Like Laury, Sounds Like Laury,” which tells the story of a woman fighting Frontotemporal Dementia, will premiere on American television next Tuesday, March 10th at 8 pm on the World Channel. The film produced by Pamela Hogan and Connie Shulman will be broadcasted as part of the third…

Researchers at Northwestern University have recently reported in the journal Brain that the amyloid plaques characteristic of Alzheimer’s disease can be found in young adult brains. The study is entitled “Neuronal amyloid-β accumulation within cholinergic basal forebrain in aging and Alzheimer’s disease.” Alzheimer’s disease…

The Irish subsidiary of biopharmaceutical company Transition Therapeutics Inc. has finished patient enrollment for its phase 2 clinical study to assess a novel therapy for mild, moderate and severe Alzheimer’s disease. Transition Therapeutics Ireland Limited (TTIL) will now evaluate the neuropsychiatric drug candidate ELND005, expecting it…